Skip to content

Study · Randomized controlled trial · n = 30 · 2012

3 results

Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome.

Coffin ST, Black BK, Biaggioni I, Paranjape SY, Orozco C, Black PW, Dupont WD, Robertson D, Raj SR

Heart rhythm3 May 2012Cited by 63 (Europe PMC)

PMID22561596 (opens in a new tab)PMCIDPMC3419341 (opens in a new tab)DOI10.1016/j.hrthm.2012.05.002 (opens in a new tab)PepBankPUB-22561596
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with POTS, desmopressin lowered standing heart rate versus placebo (101.9 ± 14.5 versus 109.2 ± 17.4 beats/min, P <.001).

    In plain wordsIn patients with POTS, desmopressin lowered standing heart rate compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseStanding heart rate
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.2 mg · oralAs given in this study (human).

    Measurements

    Standing heart rate
    101.9 beats/min
    after DDAVP 0.2 mg (SD 14.5)
    Standing heart rate
    109.2 beats/min
    after placebo (SD 17.4)

    Source sentences

    Summary
    The standing heart rate was significantly lower following DDAVP than placebo (101.9 ± 14.5 beats/min vs 109.2 ± 17.4 beats/min; P <.001).
    2 context sentences
    Summary · context
    In this protocol, patients with POTS (n = 30) underwent acute drug trials with DDAVP 0.2 mg orally and placebo, on separate mornings, in a randomized crossover design.
    Summary · context
    Blood pressure, heart rate, and symptoms were assessed while seated and after standing for up to 10 minutes prior to and hourly for 4 hours following study drug.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with POTS, desmopressin did not affect standing blood pressure (P = .28).

    In plain wordsIn patients with POTS, desmopressin did not change standing blood pressure compared with placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeStanding blood pressure
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.2 mg · oralAs given in this study (human).

    Measurements

    P value, standing blood pressure DDAVP versus placebo
    0.28 P
    DDAVP 0.2 mg versus placebo

    Source sentences

    Summary
    Standing blood pressure was not affected (P = .28).
    2 context sentences
    Summary · context
    In this protocol, patients with POTS (n = 30) underwent acute drug trials with DDAVP 0.2 mg orally and placebo, on separate mornings, in a randomized crossover design.
    Summary · context
    Blood pressure, heart rate, and symptoms were assessed while seated and after standing for up to 10 minutes prior to and hourly for 4 hours following study drug.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In POTS, symptom scores changed from 18 ± 18 to 13 ± 15 AU with desmopressin versus 18 ± 17 to 19 ± 16 AU with placebo at 2 hours (P = .010).

    In plain wordsIn patients with POTS, desmopressin improved symptoms at 2 hours compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseSymptom burden at 2 hours
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Symptom Burden · Whole body
    Studied dose
    0.2 mg · oralAs given in this study (human).

    Measurements

    Symptom burden score
    18 AU
    DDAVP before dose (SD 18)
    Symptom burden score
    13 AU
    DDAVP at 2 hours (SD 15)
    Symptom burden score
    18 AU
    placebo before dose (SD 17)
    Symptom burden score
    19 AU
    placebo at 2 hours (SD 16)

    Source sentences

    Summary
    The symptom burden improved with DDAVP (from a score of 18 ± 18 arbitrary units [AU] to 13 ± 15 AU at 2 hours) compared with placebo (from 18 ± 17 AU to 19 ± 16 AU; P = .010).
    2 context sentences
    Summary · context
    In this protocol, patients with POTS (n = 30) underwent acute drug trials with DDAVP 0.2 mg orally and placebo, on separate mornings, in a randomized crossover design.
    Summary · context
    Blood pressure, heart rate, and symptoms were assessed while seated and after standing for up to 10 minutes prior to and hourly for 4 hours following study drug.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.